ArticleBMC ophthalmology2026
Clinical outcomes of the Yamane technique: visual and refractive results and IOL tilt after secondary lens implantation.
Article in BMC ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Miri 4-points marker: a low-cost marking device for flanged intrascleral intraocular lens fixation with modified Yamane technique.BMC ophthalmology · 2026Article
- Functional and anatomical outcomes of Yamane technique-based scleral fixation after complicated cataract surgery versus IOL extraction.BMC ophthalmology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo evaluate refractive outcomes and intraocular lens (IOL) tilt following secondary implantation using the Yamane technique and to assess the relationship between tilt and refractive predictability compared with standard phacoemulsification.
methodsThis retrospective comparative study included 19 eyes (16 patients) treated with the Yamane technique and 18 eyes (16 patients) undergoing uncomplicated phacoemulsification between 2022 and 2024. Pre- and postoperative best-corrected visual acuity (BCVA) were recorded. Refractive prediction error (RPE), mean absolute error (MAE), and median absolute error (MedAE) were analyzed. IOL tilt was assessed using anterior segment optical coherence tomography (AS-OCT) at least six weeks postoperatively.
resultsThe mean best-corrected visual acuity (BCVA, logMAR) improved significantly in both groups-from 0.61 ± 0.39 to 0.10 ± 0.10 in the Yamane group (p < 0.0001) and from 0.81 ± 0.91 to 0.13 ± 0.32 in the control group. The mean refractive prediction error (RPE) was 0.81 ± 0.97 D in the Yamane group and 0.01 ± 1.08 D in the control group. Corresponding mean absolute error (MAE) values were 1.05 ± 0.69 D and 0.69 ± 0.82 D, with median absolute errors (MedAE) of 0.86 D and 0.56 D, respectively. The average intraocular lens (IOL) tilt was greater in the Yamane group (3.79°) than in the control group (0.69°). In the Yamane group, the highest tilt was observed at the 60° meridian (4.70°), and the lowest at the horizontal meridian (2.36°). In contrast, in the control group, the greatest tilt occurred at the 90° meridian (0.81°) and the smallest at the horizontal meridian (0.62°). A significant positive correlation was found between vertical IOL tilt (90°) and RPE in the Yamane group (ρ = 0.41, p < 0.05). No significant correlations were observed between tilt at other meridians and BCVA, MAE, or RPE.
conclusionThe Yamane technique provides excellent postoperative visual outcomes despite greater IOL tilt compared with standard pseudophakia. Only vertical tilt correlated with refractive prediction error, suggesting a mild hyperopic trend. The method represents a safe and effective alternative for posterior chamber IOL fixation in eyes lacking capsular support.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.